阿扎胞苷用于治疗患有骨髓增生异常综合症的患者。
Azacitidine is used to treat patients with myelodysplastic syndromes.
他的团队探讨骨髓增生异常综合征的患者血红蛋白合成异常的情况。
His team investigated the state of abnormal composition of hemoprotein in myelodysplastic syndrome.
骨髓增生异常综合征是一种造血干细胞克隆异常性疾病。
Myelodysplastic syndrome (MDS) is a clonal disorder of the hematopoietic stem cell.
目的探讨小儿骨髓增生异常综合征（MDS）的临床特点。
AbstractObjectiveTo study the clinical characteristics and prognosis factors of myelodysplastic syndrome (MDS) in children.
结论：骨髓活检是确诊低增生型骨髓增生异常综合征的必要手段。
Conclusion: the diagnose of hypoplastic MDS depends on the trephine biopsy.
目的探讨骨髓增生异常综合征（MDS）合并自身免疫性疾病的特点。
Objective To explore the character of the myelodysplastic syndrome(MDS) with autoimmune disorders (AID).
目的探讨免疫细胞化学法在骨髓增生异常综合征（MDS）诊断价值。
Objective To explore the value of immunocytochemistry in diagnosis of myelodysplastic syndromes( MDS).
我们研究了硼替佐米单药在骨髓增生异常综合征中应用的有效性和安全性。
We performed a study on efficacy and safety of bortezomib as a single agent in patients with myelodysplastic syndromes (MDS).
骨髓增生异常，往往伴有低血小板计数，其中某些病人有向白血病转化的倾向。
Myelodysplasia, which is associated with low platelet counts, predisposes some patients to leukemia.
目的：评估骨髓活检在骨髓增生异常综合征尤其是低增生型病例时的诊断价值。
Objective:To explore the value of bone marrow biopsy in diagnosing Myelodysplastic Syndrome(MDS) especially in the cases of MDS with hypoplasia.
多大剂量？多少频率？多长时间？骨髓增生异常综合征新疗法的临床应用指南。
How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes.
方法10例19 ~58岁骨髓增生异常综合征的患者，选择部分脾动脉栓塞术治疗。
Methods 10 patients, ages: 19 ~ 58 years old, troubling with MDS, accepted splenic artery part embolization.
实验证明：T - 2毒素可抑制肿瘤细胞生长，对骨癌及骨髓增生异常有良好的杀伤。
The experiment shows that the T-2 toxin is capable of inhibiting the growth of tumor cells and has good killing effect on the bone cancers and myeloproliferative disorder.
本研究探讨血小板糖蛋白特异性抗体在骨髓增生异常综合征（MDS）患者发病中的作用。
The aim of this study was to find platelet specific autoantibodies against glycoproteins in myelodysplastic syndrome(MDS)and to explore its role in pathogenesis of MDS.
丙卡巴肼、氮芥和异环磷酰胺：可增加患骨髓增生异常综合症和急性粒细胞白血病的风险。
Procarbazine, nitrogen mustard, and ifosfamide, which can increase risk for myelodysplastic syndromes and acute myelogenous leukemia.
骨髓增生异常综合征（MDS）患者的外周血白细胞减少、免疫功能低下和感染都是临床不可避免的问题。
The infection'manifestation with the decreased white blood cell and immune function is an unavoidable problem in the patients with myelodysplastic syndrome (MDS).
提示在所检病例中存在HHV?6感染，其中与急性白血病、淋巴瘤及骨髓增生异常综合症关系尤为密切。
The results show that the examined patients are infected by HHV 6, which has a good relationship with leukemia, lymphoma, myeloproliferative disorder syndrome, and multiple myeloma.
氮杂胞苷（Azacitidine），用于治疗骨髓增生异常综合征（MDS）一种罕见的恶性血液肿瘤。
Azacitidine is used to treat patients with myelodysplastic syndromes (usually abbreviated, a bit oddly, to MDS), a group of rare and deadly blood malignancies.
目的：调查白血病和骨髓增生异常综合征(MDS)患者红细胞酶和同工酶谱改变的患病率，并研究其临床意义。
Objective: To define the prevalence of acquired red cell enzymopathy in leukemia and MDS patients and explore its clinical significance.
结果联合治疗苯中毒中，再障2例均治愈，1例骨髓增生异常综合征(MDS)明显进步，1例急性造血停滞治愈。
Results 2 cases of aplastic anemia were cured and 1 case MDS was improved and 1 cured of stasis to produce blood.
我们需要新药和新的综合疗法来进一步改善治疗结果，并找寻针对白血病，淋巴瘤，骨髓增生异常综合症的治疗方法。
New drugs and new combinations of therapies are needed to further improve outcomes and find cures for individuals with leukemia, lymphoma and myelodysplastic syndromes.
目的：探讨糖基磷脂酰肌醇锚蛋白（GPIAP）在骨髓增生异常综合征（MDS）患者外周血细胞上的表达情况。
Objective:To investigate the expression of glycosylphosphatidylinositol anchored proteins(GPI AP:CD55, CD59) on peripheral erythrocytes and granulocytes in patients with myelodysplastic syndrome(MDS).
结论：骨髓活组织检查对于骨髓增生异常综合征（MDS）的阶段划分直观、明了，尤其在骨髓干抽病例更有其优越性；
Conclusion:It is simplicity and directly that to distinguished the stage of MDS with bone marrow biopsy; and for the cases of dry tap bone marrow aspiration was more useful.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征的治疗。 其2009年的销售额为17亿美元。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
阳性对照组骨髓中有核细胞增生减低及明显减低，粒细胞系统形态异常。
Marrow in positive control group was hypoplastic or marked hypoplastic, and morphology of granulocyte series was abnormal.
比较24例骨髓异常增生综合征难治性贫血与59例慢性再生障碍性贫血的临床特点和实验室资料。
Methods The clinical characteristics and experimental data of 24 patients with MDS-RA and 59 cases with CAA were analysed.
它曾被报告与淋巴母细胞转变相关的急性骨髓性白血病、骨髓增生性疾病、脊髓发育不全症等等，甚至于那些不具已知的血液学异常相关的病人们身上。
It has been reported in association with acute myeloid leukemia, myeloproliferative disorders, and myelodysplasia in blast transformation, as well as in patients with no known hematological disorders.
多发性骨髓瘤是一种浆细胞恶性增生，单克隆免疫球蛋白合成异常的恶性疾病。
Multiple myeloma is a vicious monoclonal B - cell disease with plasmacyte proliferating slowly.
多发性骨髓瘤是一种浆细胞恶性增生，单克隆免疫球蛋白合成异常的恶性疾病。
Multiple myeloma is a vicious monoclonal B - cell disease with plasmacyte proliferating slowly.
应用推荐